142 related articles for article (PubMed ID: 35369117)
1. Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?
Kang WZ; Wang BZ; Li DF; Jiang ZC; Xiong JP; Li Y; Jin P; Shao XX; Hu HT; Tian YT
Can J Gastroenterol Hepatol; 2022; 2022():8178184. PubMed ID: 35369117
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a multicentre study.
Saxena N; Hartman M; Aziz R; Rapiti E; Bhoo Pathy N; Lim SE; Iau P; Taib NA; Schaffar R; Neyroud-Caspar I; Yip CH; Lee SC; Verkooijen HM
Eur J Cancer; 2011 May; 47(8):1186-92. PubMed ID: 21239165
[TBL] [Abstract][Full Text] [Related]
3. Total Lymph Node Yield Is Associated with Prolonged Survival after Neoadjuvant Chemotherapy in ypN0 Gastric Cancer Patients.
Li W; Shao X; Ma F; Wang B; Xue L; Hu H; Kang W; Xiong J; Tian Y
Oncol Res Treat; 2023; 46(7-8):287-295. PubMed ID: 37302386
[TBL] [Abstract][Full Text] [Related]
4. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
[TBL] [Abstract][Full Text] [Related]
5. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of pathological node status after neoadjuvant radiotherapy for rectal cancer.
Duchalais E; Glyn Mullaney T; Spears GM; Kelley SR; Mathis K; Harmsen WS; Larson DW
Br J Surg; 2018 Oct; 105(11):1501-1509. PubMed ID: 29663352
[TBL] [Abstract][Full Text] [Related]
7. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients.
Wu L; Xing Z; Huang M; Yu H; Qin Y; Jin Q; Zhou Z; Chen J
J Surg Oncol; 2022 Dec; 126(8):1403-1412. PubMed ID: 36001384
[TBL] [Abstract][Full Text] [Related]
8. Using the Lymph Node Ratio to Evaluate the Prognosis of Stage II/III Breast Cancer Patients Who Received Neoadjuvant Chemotherapy and Mastectomy.
Wu SG; Li Q; Zhou J; Sun JY; Li FY; Lin Q; Lin HX; Gaun XX; He ZY
Cancer Res Treat; 2015 Oct; 47(4):757-64. PubMed ID: 25672578
[TBL] [Abstract][Full Text] [Related]
9. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
[TBL] [Abstract][Full Text] [Related]
10. Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study.
Sun C; Niu P; Zhang X; Zhao L; Wang W; Luan X; Han X; Chen Y; Zhao D
BMC Cancer; 2023 Oct; 23(1):996. PubMed ID: 37853387
[TBL] [Abstract][Full Text] [Related]
11. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.
Schneider PM; Baldus SE; Metzger R; Kocher M; Bongartz R; Bollschweiler E; Schaefer H; Thiele J; Dienes HP; Mueller RP; Hoelscher AH
Ann Surg; 2005 Nov; 242(5):684-92. PubMed ID: 16244542
[TBL] [Abstract][Full Text] [Related]
12. Postmastectomy Radiation Therapy Based on Pathologic Nodal Status in Clinical Node-Positive Stage II to III Breast Cancer Treated with Neoadjuvant Chemotherapy.
Huang Z; Zhu L; Huang XB; Tang Y; Rong QL; Shi M; Wang WH; Tie J; Shen LF; Chen JY; Zhang J; Wu HF; Cheng J; Liu M; Tan YT; Ma CY; Wang SL; Li YX
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):1030-1039. PubMed ID: 32585337
[TBL] [Abstract][Full Text] [Related]
13. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
[TBL] [Abstract][Full Text] [Related]
14. Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy.
Koo T; Song C; Kim JS; Kim K; Chie EK; Kang SB; Lee KW; Kim JH; Jeong SY; Kim TY
PLoS One; 2015; 10(9):e0138728. PubMed ID: 26381522
[TBL] [Abstract][Full Text] [Related]
15. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A.
Fujitani K; Nakamura K; Mizusawa J; Kuwata T; Shimoda T; Katayama H; Kushima R; Taniguchi H; Yoshikawa T; Boku N; Terashima M; Fukuda H; Sano T; Sasako M;
Gastric Cancer; 2021 Jan; 24(1):197-204. PubMed ID: 32572792
[TBL] [Abstract][Full Text] [Related]
16. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
[TBL] [Abstract][Full Text] [Related]
17. Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.
Peng YF; Yu WD; Pan HD; Wang L; Li M; Yao YF; Zhao J; Gu J
World J Gastroenterol; 2015 Feb; 21(6):1851-6. PubMed ID: 25684951
[TBL] [Abstract][Full Text] [Related]
18. Clinical assessment of tumor regression grade systems in gastroesophageal adenocarcinoma following neoadjuvant chemotherapy.
Lütken C; Sheikh K; Willemoe GL; Achiam MP; Hasselby JP
Pathol Res Pract; 2021 Aug; 224():153538. PubMed ID: 34243107
[TBL] [Abstract][Full Text] [Related]
19. Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?
Knight WRC; Baker CR; Griffin N; Wulaningsih W; Kelly M; Davies AR; Gossage JA;
Br J Cancer; 2021 May; 124(10):1653-1660. PubMed ID: 33742143
[TBL] [Abstract][Full Text] [Related]
20. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery.
Becker K; Reim D; Novotny A; Zum Büschenfelde CM; Engel J; Friess H; Höfler H; Langer R
Ann Surg; 2012 Dec; 256(6):1002-7. PubMed ID: 22968067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
